Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Pharmaceutical Executive September 1, 2010	Pharm Exec's Ninth Annual Industry Audit Professor Bill Trombetta takes a snapshot of the "Glamour 24" companies shaping the pharma industry this year and beyond.
Pharmaceutical Executive September 1, 2014 Bill Trombetta	13th Annual Industry Audit After a dip into negative territory in 2012, 2013 delivered a resurgence in sales revenues, but the turnaround only spotlights a larger trend: the growing divide between the big Pharmas and the more nimble players.
Pharmaceutical Executive September 1, 2012 Bill Trombetta	Pharm Exec's 11th Annual Industry Audit: Busting the Tape With pharmaceuticals are eyed as a commodity purchase, those traditional high margins are getting harder to find. Shareholder value and profits now depends on finding pockets of "good" growth, in segments with long-term potential in serving an unmet medical need, with fewer players.
Pharmaceutical Executive September 1, 2006 Bill Trombetta	Industry Audit This fifth annual report dives deep into the numbers and comes up with the pharmaceutical industry's true top performers.
Pharmaceutical Executive September 1, 2005 Bill Trombetta	2005 Industry Audit Who's really on top in the pharmaceutical industry?
Pharmaceutical Executive June 1, 2009	Stealth Pharmas These noteworthy pharmas and biotechs generally fly under the radar (ergo "stealth") of the mainstream media.
Pharmaceutical Executive April 1, 2007 Bill Trombetta	Stealth Pharmas Big Pharma is different from the thousands of biotechs, specialty pharmas, generics makers, and other companies that make up Stealth Pharma. Yes, they have more money. But in what other ways are they different? And can we learn anything from the way Stealth Pharma competes?
Pharmaceutical Executive September 1, 2014 William Looney	13 Years Right Pharm Exec's latest Industry Audit sticks to the series' longtime standard of emphasizing transparent indicators of shareholder value.
The Motley Fool October 18, 2010 Gerard Torres	Every Investor Should Know This Stock Tool Use DuPont analysis to breakdown the profitability of stocks.
Pharmaceutical Executive January 1, 2014 Stan Bernard	The 7 Habits of Highly Effective Competitions Lessons to win in a shifting market dynamic
Pharmaceutical Executive June 9, 2014 Cliff Kalb	The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard.
Investment Advisor January 2007 Mark Tibergien	Analyze This Benchmark your financial advisory firm against itself, as well as the competition.
The Motley Fool September 22, 2011	Investing 101: 10 Highly Profitable and Undervalued Stocks If you're interested in searching for profitable companies, this list might interest you: Calamos... Capital One Financial... Discover... East West Bancorp... FBL Financial... KeyCorp... Protective Life... Symetra Financial... Torchmark... LIN TV...
The Motley Fool April 28, 2009 Katrina Chan	5 Numbers You Can't Afford to Miss Today's topic is basic financial metrics and concepts. These concepts will help any investor examine companies with a more critical eye.
Investment Advisor July 2009 Mark Tibergien	Formulas for Success: Physician, Heal Thy Business Owners of advisory firms have a little breathing room to make clear-headed decisions. But not a lot of time.
The Motley Fool May 23, 2011 Andrew Tonner	Does Amgen Deserve a Spot in Your Portfolio? Depending on your assessment of future growth, Amgen could certainly make a nice addition to your portfolio.
The Motley Fool January 13, 2011 Seth Jayson	Does Novo Nordisk Measure Up? With recent TTM margins all exceeding historical averages, Novo Nordisk looks like it's doing fine.
The Motley Fool January 28, 2005 Stephen D. Simpson	An Understated Scandinavian The Danish pharmaceutical may not be quite cheap enough to be a true value, but investors looking for a solid growth stock should see what's new with Novo Nordisk.
Pharmaceutical Executive September 1, 2012 William Looney	The Margin Call Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
Pharmaceutical Executive July 1, 2009 Stan Bernard	Forget Brand vs. Brand--This is War Increasingly, pharma companies are expanding from brand vs. brand to battle at the franchise, portfolio, and corporate levels.
Pharmaceutical Executive March 1, 2006 Cacciotti & Shew	Pharma's Next Top Model: Slimmer Business Models After almost two decades of blockbuster-driven prosperity, the model for success in pharmaceuticals has broken down. The path forward, once clear, is no longer obvious.
The Motley Fool August 10, 2010 Todd Wenning	Dividend Report Card: AstraZeneca Does this drugmaker's dividend pass the test?
The Motley Fool October 22, 2010 Anand Chokkavelu	7 Big Pharma Stocks Near 52-Week Lows Trolling the bottom for upside potential.
The Motley Fool December 27, 2005	Foolish Fundamentals: The Income Statement A look at how companies report their sales and profits and what it means to investors.
The Motley Fool May 25, 2005	Behold the Income Statement The income statement is easy -- and important -- to understand.
The Motley Fool January 25, 2008 Brian Orelli	Where the Big Margins Are Drug company investors get to enjoy such high gross margins, but there's generally only so much improvement that a company can make when it starts from such a high point. Take a look at some pharma companies that are succeeding to do just that.
Pharmaceutical Executive January 21, 2014 Tim Powell	Innovation: The Moneyball Test Successful innovation now has to align with key metrics of value; can an old baseball metaphor help guide the way?
The Motley Fool January 31, 2007 Brian Lawler	Novo Nordisk Knows Sales Growth Diabetes care leads the way for this Danish drugmaker. Investors willing to do a little extra financial sleuthing will find a pharmaceutical company that's the global leader in a rapidly growing health-care segment.
Pharmaceutical Executive November 1, 2014 William Looney	Dane in America Jesper Hoiland, Novo Nordisk's President for North America, assesses the challenges and opportunities during his first year at the helm of the diabetes franchise leader's biggest affiliate market.
The Motley Fool July 28, 2010 Sean Sun	Risk Report Card: Procter & Gamble The power of its brands, from its Gillette razors to its Pampers diapers, gives it premium pricing power and an edge over its competitors.
The Motley Fool June 26, 2009 Selena Maranjian	Pursuing Profits? Meet Margins! Baffled by talk of gross, operating, or net margins? We're here to help.
The Motley Fool June 9, 2005 Richard Gibbons	Buying on Margins Profit margins are one useful tool for finding great stock values.
The Motley Fool January 18, 2011 Jim Royal	How Do These Biotechs Really Make Their Money? Break it down using the Dupont formula.
The Motley Fool May 25, 2011 Eben Esterhuizen	Value Ideas: Highly Profitable Stocks, Undervalued Relative to Revenue Growth Which of these names are you most bullish on?
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
Pharmaceutical Executive December 1, 2008 Walter Armstrong	The New Deals Everything you wanted to know about the year's most important deals, and what to watch for in the future.
CIO April 1, 2006 Christopher Koch	The Metrics Trap...And How to Avoid It Calculating IT spending as a percentage of overall revenue is easy, popular... and misleading. There's gotta be a better way. In fact, there are several.
Pharmaceutical Executive April 1, 2006 Christensen, McLaughlin & Wunker	The Road to Nowhere? More effective drugs? Another dead end. But patients open their wallets when a "good enough" drug gets better.
The Motley Fool July 27, 2005 Selena Maranjian	Cracking the Accounting Code Financial statements are less confusing and more informative than you think. By learning to make sense of balance sheets, income statements, and statements of cash flows, you can put some profitable ideas in your portfolio.
The Motley Fool August 26, 2005 Nathan Parmelee	Restoration Hardware: Still Under Construction The company is making improvements, the specialty retailer has yet to reward investors with a regular profit -- and there's no telling when or if it might start doing so.
IndustryWeek July 20, 2011	IW 50 Best Manufacturers: Methodology How IW ranked the Top 50
The Motley Fool December 14, 2006 John Finneran	Bank Efficiency: Measure With Care Here are some factors investors need to consider when measuring an efficiency ratio for bank productivity.
The Motley Fool August 8, 2008 Brian Lawler	Not Bad, Novo Nordisk The drugmaker's performance is better than its numbers suggest.
The Motley Fool April 30, 2011 Brian Orelli	No Long-Term Guidance? No Problem! Looking good, Merck.
The Motley Fool August 24, 2011 Andrew Tonner	Does Abbott Laboratories Look Like a Winning Investment? A quick check of their numbers shows us that Abbott Labs looks reasonably attractive.
The Motley Fool February 10, 2010 Brian Orelli	Icahn's Smiling -- Should We Be? Biogen Idec's fourth quarter results must have made Carl Icahn smile. But the guidance for next year gives pause.
The Motley Fool August 31, 2006	Foolish Fundamentals: Margins Margins are important, but how you use margin information is more important to your investing success. Don't stay on the surface when analyzing margins. Your portfolio will thank you for it later.
Pharmaceutical Executive January 1, 2009 Walter Armstrong	Up in the Air If pharma execs start upping their consumption of antihypertensives and anxiolytics (all branded, of course) in the months to come, it won't be a huge surprise. The industry faces a truly unprecedented number of political and policy challenges.
The Motley Fool July 27, 2010 Sean Sun	Risk Report Card: Amazon.com What's really interesting about Amazon is that it turns the traditional notions about technology-based companies on their head.